Trichosporon asahii (formerly known as T. beigelii) is an emerging, life-threatening opportunistic pathogen, especially in severely granulocytopenic patients with underlying hematological malignancies. Other reported predisposing factors for infection with this pathogen include organ transplantation, extensive burns, human immunodeficiency virus infection, corticosteroid therapy, prosthetic valve surgery, and peritoneal dialysis. We report a 53-year-old nongranulocytopenic female with secondary hemochromatosis, who developed nosocomial fungemia caused by T. asahii. This case suggests that clinicians should be aware that T. asahii fungemia can develop in nongranulocytopenic patients with secondary hemochromatosis.
Introduction
Over the past decade, Trichosporon spp. have been recognized as opportunistic pathogens capable of causing invasive infections, especially in immunosuppressed patients. 1 Infection with Trichosporon spp. has been associated with a high mortality rate in a retrospective study. 2 These pathogens have rarely been reported to cause nosocomial infections in the literature. 3 Here, we report the case of a nongranulocytopenic patient with nosocomial fungemia caused by Trichosporon asahii (formerly known as T. beigelii).
Case Report
A 53-year-old female was admitted to our hospital with a 2-day history of lower back soreness and shortness of breath. She had also had 17-year history of paroxysmal nocturnal hemoglobinuria and anemia. Frequent blood transfusions resulted in secondary hemochromatosis and chronic renal insufficiency. A prior renal biopsy showed tubular deposition of hemosiderin. On admission, she appeared pale and dyspneic with a blood pressure of 95/41 mmHg, a heart rate of 118 beats/min and a respiratory rate of 28 breaths/min. Physical examination showed ecchymoses and pitting edema in the lower extremities. The white cell count was 7,500/mm 3 (96% neutrophils); hemoglobin was 9.7 g/dL; and hematocrit was 27.7%.
Nosocomial 
Discussion
In the past 3 decades, the non-Candida yeast Trichosporon spp. have been increasingly recognized as opportunistic pathogens capable of causing invasive infections, especially in immunosuppressed patients. 1 Guého et al described human colonization with Trichosporon spp. 5 The gastrointestinal tract, skin, and mucosal surfaces have been reported as the sites of colonization, and Trichosporon spp. have also been detected in stool, central venous catheter, sputum, and hair. Thirty-eight Trichosporon spp. have been described in the current literature, and among these, eight are considered as potential human pathogens: T. asahii, T. asteroides, T. cutaneum, T. inkin, T. mucoides, T. ovoides, T. domesticum, and T. montevideense. 6 Invasive Trichosporon infections are usually preceded by respiratory or gastrointestinal tract colonization, and are commonly associated with the use of central venous catheters. 6 More recently, T. asahii and T. mucoides have emerged as major opportunistic pathogens responsible for invasive infections in immunosuppressed patients, and T. asahii has been described as the most frequently isolated species. 5, 6 Trichosporon spp. are characterized by their ability to form hyphae, pseudohyphae, arthroconidia and blastoconidia. 6 There has been a considerable increase in the incidence of the invasive Trichosporon infection over the past 2 decades. Invasive infections are more common in patients with hematological malignancies.
2 A shift to a predominance of catheter-related fungemia, without evidence of organ involvement, has been reported. 10 The proposed explanation for this change is the increased use of central venous catheters and the widespread use of fluconazole prophylaxis. Wolf et al reported six nongranulocytopenic patients with invasive Trichosporon infection, in whom the isolates of T. asahii shared a similar phenotype and genotype, thereby suggesting a common nosocomial origin. 3 In a recent review of the literature, Trichosporon fungemia was found to occur in 74% of all reported Trichosporon spp. infections; 50% of the cases were classified as disseminated, 16% of the cases had disease restricted to the lung, and 3.2% had focal hepatosplenic involvement. 2 Although Trichosporon spp. have most often been implicated in invasive infections in immunosuppressed hosts, trichosporonosis in immunocompetent patients has rarely been reported.
Nosocomial Trichosporon asahii fungemia predisposing factors include organ transplantation, extensive burns, human immunodeficiency virus infection, corticosteroid therapy, prosthetic valve surgery, and peritoneal dialysis. 3, 12 Hemochromatosis is a separate risk factor for trichosporonosis. 12 Two potential mechanisms have been described that increase the risk of fungal infection. First, iron serves as a nutrient for fungal growth, and is an important cofactor for enzymes involved in many basic cellular functions. 13 Trichosporon grows rapidly in vitro in iron-supplemented media, and iron overload has been implicated as a factor in invasive Trichosporon infections. 12 Second, an environment free of excess iron is required for the effective innate and acquired immune responses.
14 Iron overload decreases T-cell antifungal immunity, natural killer cell activity, and the phagocytic capacity of neutrophils and monocytes, thereby greatly increasing the possibility of invasive fungal infections. 15, 16 Although there have been many advances in antifungal treatment of invasive fungal infections, 17 the optimal therapy for trichosporonosis has yet to be identified. The new triazole voriconazole, alone or in combination, is probably the drug of choice for this infection, especially in a granulocytopenic patient. 18, 19 In patients who cannot be treated with voriconazole because of its side effects, amphotericin B, flucytosine, fluconazole, and itraconazole might be alternative antifungals, 2 although multidrug resistance to these agents leading to treatment failure has been reported. 3 Other new triazoles, namely, posaconazole and ravuconazole, have also shown potent in vitro activity against isolates of T. asahii and other Trichosporon species. 20 Reportedly, echinocandins have low activity against Trichosporon spp. and are not recommended for the treatment of trichosporonosis. 17, 21 The prognosis of invasive trichosporonosis has been dismal because the crude mortality rate is as high as 77% in published cases. 3 The poor results of treatment are mostly due to the advanced nature of the underlying illness.
In conclusion, T. asahii causes life-threatening infections, particularly in granulocytopenic patients. It is important to consider that emerging Trichosporon spp. infections are usually difficult to diagnose, are refractory to conventional antifungal agents, and are associated with a high mortality rate. 2, 6 Early diagnosis is crucial for successful therapy. Clinicians should be aware that Trichos poron fungemia might develop in patients with secondary hemochromatosis. Early detection and accurate identification of this unusual pathogen are necessary to provide specific and timely antifungal therapy, and offer the patient a better chance of survival.
